文献速递细菌感染、耐药与抗菌药物医院感染防控

替莫西林与头孢噻肟治疗成人发热性尿路感染的临床和微生物学疗效及其对肠道微生物群的影响:一项在瑞典开展的随机多中心临床试验

The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: a randomised multicentre clinical trial in Sweden.
PubMed 文献 · Lancet Infect Dis · 2021-10-28

该研究在瑞典12家医院纳入152例疑似或确诊发热性尿路感染的成人住院患者,随机分配接受替莫西林或头孢噻肟静脉治疗。主要复合终点显示替莫西林组肠道定植耐药肠杆菌目或产毒艰难梭菌的比例低于头孢噻肟组,风险差为-22%(95%CI -42%至-3%),表明替莫西林对肠道微生物群干扰更小。

要点

  • 替莫西林组主要复合终点发生率为26%(18/68),头孢噻肟组为48%(30/62)。
  • 风险差为-22%(95%CI -42%至-3%),显示替莫西林优效。
  • 替莫西林组40例(52%)报告43起不良事件,头孢噻肟组34例(45%)报告46起。

核心结论

  • 替莫西林对第三代头孢菌素敏感性降低的肠杆菌目的选择性低于头孢噻肟,可能成为发热性尿路感染经验性治疗的有利替代选择。

研究设计与样本

  • 在瑞典12家医院开展的随机、多中心、优效性、开放标签4期试验,纳入疑似或确诊发热性尿路感染(复杂性或非复杂性)的成人住院患者,随机1:1分配接受替莫西林2g或头孢噻肟1-2g,每8小时静脉给药一次。
  • 共筛选207例患者,排除55例,最终152例随机分组:替莫西林组77例(51%),头孢噻肟组75例(49%)。

主要发现

  • 主要复合终点(对第三代头孢菌素敏感性降低的肠杆菌目定植和/或产毒艰难梭菌定植)在替莫西林组68例中18例(26%)发生,头孢噻肟组62例中30例(48%)发生,风险差-22%(95%CI -42%至-3%)。
  • 替莫西林组77例中40例(52%)报告43起不良事件,头孢噻肟组75例中34例(45%)报告46起不良事件,大多数为轻至中度。
  • 替莫西林组21例(27%)和头孢噻肟组17例(23%)发生被认为与研究药物相关的不良事件。

关键数值与推荐

  • 纳入标准:至少一项肾盂肾炎体征或症状(胁腹痛、肋脊角压痛、尿频或尿急改变或排尿困难),体温≥38.0°C,尿试纸阳性(亚硝酸盐和/或白细胞),且有静脉抗生素治疗指征。
  • 主要复合终点为对第三代头孢菌素敏感性降低的肠杆菌目定植和/或产毒艰难梭菌定植。

临床怎么用

  • 作者认为替莫西林对第三代头孢菌素敏感性降低的肠杆菌目的选择性低于头孢噻肟,可能成为发热性尿路感染经验性治疗的有利替代选择。
  • 作者认为使用该抗生素可能减少这些病原体的医院传播和医疗保健相关感染。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Use of third-generation cephalosporins, such as cefotaxime, is associated with an increased risk of selection for antimicrobial resistance, so alternative antibiotics need to be considered. The aim of the present study was to evaluate intestinal colonisation with third-generation cephalosporin-resistant pathogens following use of temocillin-an alternative antibiotic to cefotaxime that is potentially less prone to disturbing the intestinal microbiota-in empirical treatment of febrile urinary tract infection (UTI). METHODS: We did a randomised, multicentre, superiority, open-label phase 4 trial in patients who had been admitted to inpatient care in 12 Swedish hospitals with suspected or diagnosed febrile UTI (complicated or uncomplicated). To meet inclusion criteria, a patient was required to have at least one sign or symptom of pyelonephritis (ie, flank pain; costovertebral angle tenderness; and changes to urinary frequency or urgency or dysuria), a fever of 38·0°C or higher, and a positive urine dipstick (for nitrites, white blood cells, or both). Participants were also required to have an indication for intravenous antibiotic treatment. Participants were randomly assigned (1:1) to receive either 2 g temocillin or 1-2 g cefotaxime, by local investigators opening consecutive sealed randomisation envelopes that were generated centrally in advance. Both drugs were administered intravenously every 8 h. The trial was open label for investigators and patients, but those doing the microbiological analyses were masked to the groups. Participants were treated with antibiotics for 7-10 days (or up to 14 days if they had bacteraemia), at least 3 days of which were on the study drug; at day 4 and later, participants who were showing improvement could be given an oral antibiotic (ciprofloxacin, ceftibuten, cefixime, or co-trimoxazole). Patients not showing improvement were regarded as having treatment failures. Rectal swabs were collected at three timepoints: at baseline (before the first dose), after the last dose of study drug, and 7-10 days after treatment stopped. The composite primary outcome was colonisation with Enterobacterales with reduced susceptibility to third-generation cephalosporins, or colonisation with toxin-producing Clostridioides difficile, or both, to evaluate disturbance of the intestinal microbiota. The study is registered in the EU Clinical Trials Register (EudraCT 2015-003898-15). FINDINGS: Between May 20, 2016, and July 31, 2019, 207 patients were screened for eligibility, of whom 55 patients were excluded. 152 participants were randomly assigned to groups: 77 (51%) patients received temocillin, 75 (49%) patients received cefotaxime. The composite primary endpoint was met by 18 (26%) of 68 participants receiving temocillin versus 30 (48%) of 62 patients receiving cefotaxime (risk difference -22% [95% CI -42% to -3%]), showing superiority of temocillin versus cefotaxime (ie, less disturbance of the intestinal microbiota). 43 adverse events were reported in 40 (52%) of 77 patients in the temocillin group, versus 46 adverse events in 34 (45%) of 75 patients in the cefotaxime group. Most events were of mild to moderate severity. 21 (27%) patients in the temocillin and 17 (23%) patients in the cefotaxime group had an adverse event that was considered to be associated with the study drug. INTERPRETATION: Temocillin was found to be less selective than cefotaxime of Enterobacterales with reduced susceptibility to third-generation cephalosporins, and it could therefore be a favourable alternative in the empirical treatment of febrile UTI. Use of this antibiotic could reduce hospital transmission and health-care-associated infections by these pathogens. FUNDING: Public Health Agency of Sweden.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Edlund C, Ternhag A, Skoog Ståhlgren G, et al. The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: a randomised multicentre clinical trial in Sweden. Lancet Infect Dis. 2021. PMID: 34756180. doi:10.1016/S1473-3099(21)00407-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。